Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Impact · against what's priced in

The clinical data for zorevunersen is a positive development for both companies, but it represents a marginal catalyst for Biogen given the drug's current role as a secondary pipeline asset compared to the LEQEMBI/MS crux. Stoke Therapeutics gains a clearer valuation floor through the confirmation of durable efficacy and a defined regulatory path toward 2027.

BIIB+0.20

Not in the price yet

In context